Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 2/20 | 0.35 |
| ▸ | SKP1 | P63208 | 2/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 3/20 | 0.35 |
| ▸ | ACACA | Q13085 | 3/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 4/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784143 | 0.92 | F10 (0.37) | F10HCRTR1HCRTR2RBP4CKS1B | |
| SCHEMBL784868 | 0.90 | F10 (0.36) | F10HCRTR1HCRTR2RBP4CKS1B | |
| SCHEMBL784994 | 0.88 | TAF1 (0.38) | HCRTR1HCRTR2RBP4CXCR4 | |
| SCHEMBL791229 | 0.85 | F10 (0.38) | F10CKS1BSKP1SKP2ACACB | |
| SCHEMBL790422 | 0.83 | F10 (0.40) | F10CKS1BSKP1SKP2ACACB | |
| SCHEMBL784144 | 0.80 | TAF1 (0.40) | HCRTR1HCRTR2RBP4CXCR4 | |
| SCHEMBL784998 | 0.78 | HCRTR1 (0.39) | HCRTR1HCRTR2RBP4 | |
| SCHEMBL784596 | 0.78 | HCRTR1 (0.39) | HCRTR1HCRTR2RBP4 | |
| SCHEMBL784869 | 0.77 | TAF1 (0.37) | HCRTR1HCRTR2RBP4CXCR4 | |
| SCHEMBL803552 | 0.77 | HCRTR1 (0.38) | HCRTR1HCRTR2CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | F10 524/4885HCRTR1 214/4885HCRTR2 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.